Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Silevertinib shows strong efficacy and CNS activity in NSCLC with non-classical EGFR mutations, outperforming competitors in both mutation coverage and brain penetrance. Regulatory discussions are underway for a pivotal trial, with a phase II GBM study also progressing and financial runway secured…
Silevertinib shows strong efficacy and CNS activity in non-classical EGFR-mutated NSCLC, with a 60% response rate and 86% CNS response, and is advancing in both NSCLC and GBM. FDA feedback on pivotal trial design is expected in Q4, with trial initiation planned for mid-next year.Based on Black Diam…